Non-parenteral formulation of Remdesivir for Covid-19 treatment
Remdesivir exhibits in vitro activity against SARS-CoV-2 and was granted approval for Emergency Use. To maximize delivery to the lungs,
A forum for researchers, students and applicants in the field of cyclodextrin technology
Remdesivir exhibits in vitro activity against SARS-CoV-2 and was granted approval for Emergency Use. To maximize delivery to the lungs,
Cyclodextrin‐soluble angiotensin‐converting enzyme 2 (CD‐sACE2) inclusion compounds can be useful in the treatment of SARS‐CoV‐2 infections by blocking S‐proteins .
The New York Times published on June 22, 2020: The American biopharmaceutical company Gilead Sciences will soon start trials of